Skip to content
2000
image of Dahuang Zhechong Pill Combined with TNS4 Silencing Inhibits the NF-Κb/VEGF Pathway To Slow Down The Progression Of Pancreatic Cancer

Abstract

Introduction

Pancreatic cancer (PC) is a highly aggressive malignancy with limited treatment options and poor prognosis. Dahuang Zhechong Pill, a traditional Chinese medicine, has shown promise in inhibiting inflammation. This study investigates the effects of combining Dahuang Zhechong Pill with TNS4 silencing on PC, focusing on their combined role in suppressing PC progression and exploring potential therapeutic applications. Intellectual property implications related to this combination are also explored.

Methods

Bioinformatic analysis was used to identify the key role of TNS4 in PC. CFPAC-1 PC cells were cultured and genetically modified using lentiviral transfection to stably knock down TNS4 expression. Cell proliferation was assessed using the CCK-8 assay, while cell migration and invasion capabilities were evaluated through Transwell assays. Colony formation and flow cytometry were performed to analyze clonogenic potential and cell cycle distribution, respectively. Apoptosis was assessed using tunel staining. Subcutaneous and orthotopic tumor models were established in nude mice to investigate the effects. Mice were treated with Dahuang Zhechong Pill by oral gavage. Immunohistochemistry and immunofluorescence were employed to detect the expression of key proteins involved in the NF-κB/VEGF pathway, including E-cadherin and Vimentin. ELISA was used to measure circulating IL-17 and amylase levels in mouse serum to test inflammation response.

Results

TNS4 was upregulated in PC and positively associated with PC progression. TNS4 silencing significantly reduced CFPAC-1 cell proliferation, migration, and invasion . Flow cytometry demonstrated an increase in G0/G1 phase arrest and apoptosis in the TNS4 silencing group. Subcutaneous models showed the anti-tumor effect of TNS4 silencing. Furthermore, Dahuang Zhechong Pill treatment, when combined with TNS4 knockdown, resulted in a marked decrease in tumor size in orthotopic models. Immunohistochemical analysis revealed reduced expression of NF-κB and VEGF in tumor tissues from the combination treatment group. ELISA results indicated lower levels of serum IL-17, and amylase and higher levels of insulin in combination-treated mice.

Discussion

We proposed an innovative therapeutic patent combining traditional Chinese medicine with targeted gene silencing to inhibit PC progression. By investigating the synergistic effects of TNS4 silencing and Dahuang Zhechong Pill in suppressing the NF-κB/VEGF signaling pathway, our findings highlighted a promising strategy that targets tumor proliferation and modulates the inflammatory microenvironment in PC.

Conclusion

Dahuang Zhechong Pill, in combination with TNS4 silencing, effectively inhibits the NF-κB/VEGF pathway and inflammation response, leading to reduced PC progression. These findings suggest a potential therapeutic approach for targeting PC through the combined use of traditional Chinese medicine and gene editing.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/pra/10.2174/0115748928379439250621171215
2025-07-03
2025-09-21

  • From This Site

    /content/journals/pra/10.2174/0115748928379439250621171215
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Stoffel E.M. Brand R.E. Goggins M. Pancreatic cancer: Changing epidemiology and new approaches to risk assessment, early detection, and prevention. Gastroenterology 2023 164 5 752 765 10.1053/j.gastro.2023.02.012 36804602
    [Google Scholar]
  2. Conroy T. Pfeiffer P. Vilgrain V. Pancreatic cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann. Oncol. 2023 34 11 987 1002 10.1016/j.annonc.2023.08.009 37678671
    [Google Scholar]
  3. Bianchi A. De Castro Silva I. Deshpande N.U. Cell-autonomous cxcl1 sustains tolerogenic circuitries and stromal inflammation via neutrophil-derived tnf in pancreatic cancer. Cancer Discov. 2023 13 6 1428 1453 10.1158/2159‑8290.CD‑22‑1046 36946782
    [Google Scholar]
  4. Heo H. Kim H.J. Haam K. Epigenetic activation of tensin 4 promotes gastric cancer progression. Mol. Cells 2023 46 5 298 308 10.14348/molcells.2023.2148 36896596
    [Google Scholar]
  5. Di-Luoffo M. Pirenne S. Saandi T. A mouse model of cholangiocarcinoma uncovers a role for tensin‐4 in tumor progression. Hepatology 2021 74 3 1445 1460 10.1002/hep.31834 33768568
    [Google Scholar]
  6. Zhao X. Mai Z. Liu L. Lu Y. Cui L. Yu J. Hypoxia-driven TNS4 fosters HNSCC tumorigenesis by stabilizing integrin α5β1 complex and triggering FAK-mediated Akt and TGFβ signaling pathways. Int. J. Biol. Sci. 2024 20 1 231 248 10.7150/ijbs.86317 38164166
    [Google Scholar]
  7. Wang S. Fu J.L. Hao H.F. Jiao Y.N. Li P.P. Han S.Y. Metabolic reprogramming by traditional Chinese medicine and its role in effective cancer therapy. Pharmacol. Res. 2021 170 105728 10.1016/j.phrs.2021.105728 34119622
    [Google Scholar]
  8. Su X.L. Wang J.W. Che H. Clinical application and mechanism of traditional Chinese medicine in treatment of lung cancer. Chin. Med. J. 2020 133 24 2987 2997 10.1097/CM9.0000000000001141 33065603
    [Google Scholar]
  9. Xu W. Li B. Xu M. Yang T. Hao X. Traditional Chinese medicine for precancerous lesions of gastric cancer: A review. Biomed. Pharmacother. 2022 146 112542 10.1016/j.biopha.2021.112542 34929576
    [Google Scholar]
  10. Zhang Y. Xu H. Li Y. Sun Y. Peng X. Advances in the treatment of pancreatic cancer with traditional Chinese medicine. Front. Pharmacol. 2023 14 1089245 10.3389/fphar.2023.1089245 37608897
    [Google Scholar]
  11. Gao Y. Chen S. Sun J. Traditional chinese medicine may be further explored as candidate drugs for pancreatic cancer: A review. Phytother. Res. 2021 35 2 603 628 10.1002/ptr.6847 32965773
    [Google Scholar]
  12. He X. Liang J. Li X. Dahuang zhechong pill ameliorates hepatic fibrosis by regulating gut microbiota and metabolites. J. Ethnopharmacol. 2024 321 117402 10.1016/j.jep.2023.117402 37967779
    [Google Scholar]
  13. Ni Z.H. Wu L. Cao K.X. Investigation of the pharmacodynamic substances in dahuang zhechong pill that inhibit energy metabolism. J. Ethnopharmacol. 2020 251 112332 10.1016/j.jep.2019.112332 31669443
    [Google Scholar]
  14. Wu L. Yang F.R. Xing M.L. Multi-material basis and multi-mechanisms of the Dahuang Zhechong pill for regulating Treg/Th1 balance in hepatocellular carcinoma. Phytomedicine 2022 100 154055 10.1016/j.phymed.2022.154055 35344716
    [Google Scholar]
  15. Ghandi M. Huang F.W. Jané-Valbuena J. Next-generation characterization of the cancer cell line encyclopedia. Nature 2019 569 7757 503 508 10.1038/s41586‑019‑1186‑3 31068700
    [Google Scholar]
  16. Kong X. Liu C. Zhang Z. BATMAN-TCM 2.0: An enhanced integrative database for known and predicted interactions between traditional Chinese medicine ingredients and target proteins. Nucleic Acids Res. 2024 52 D1 D1110 D1120 10.1093/nar/gkad926 37904598
    [Google Scholar]
  17. Subramanian A. Tamayo P. Mootha V.K. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 2005 102 43 15545 15550 10.1073/pnas.0506580102 16199517
    [Google Scholar]
  18. Wu T. Hu E. Xu S. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation 2021 2 3 100141 10.1016/j.xinn.2021.100141 34557778
    [Google Scholar]
  19. Brozos-Vázquez E. Toledano-Fonseca M. Costa-Fraga N. Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection. Cancer Treat. Rev. 2024 125 102719 10.1016/j.ctrv.2024.102719 38490088
    [Google Scholar]
  20. Cai J. Chen H. Lu M. Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosis. Cancer Lett. 2021 520 1 11 10.1016/j.canlet.2021.06.027 34216688
    [Google Scholar]
  21. Caronni N. La Terza F. Vittoria F.M. IL-1β+ macrophages fuel pathogenic inflammation in pancreatic cancer. Nature 2023 623 7986 415 422 10.1038/s41586‑023‑06685‑2 37914939
    [Google Scholar]
  22. Li Y. Wang J. Wang H. The interplay between inflammation and stromal components in pancreatic cancer. Front. Immunol. 2022 13 850093 10.3389/fimmu.2022.850093
    [Google Scholar]
  23. Kemp S.B. Carpenter E.S. Steele N.G. Apolipoprotein E promotes immune suppression in pancreatic cancer through NF-κB–mediated production of CXCL1. Cancer Res. 2021 81 16 4305 4318 10.1158/0008‑5472.CAN‑20‑3929 34049975
    [Google Scholar]
  24. Shi T. Li X. Zheng J. Increased SPRY1 expression activates NF-κB signaling and promotes pancreatic cancer progression by recruiting neutrophils and macrophages through CXCL12-CXCR4 axis. Cell. Oncol. 2023 46 4 969 985 10.1007/s13402‑023‑00791‑z 37014552
    [Google Scholar]
  25. Yang J. Li X. Chen S. GPRC5A promotes gallbladder cancer metastasis by upregulating TNS4 via the JAK2–STAT3 pathway. Cancer Lett. 2024 598 217067 10.1016/j.canlet.2024.217067 38942137
    [Google Scholar]
  26. Zhao H. Wu L. Yan G. Inflammation and tumor progression: Signaling pathways and targeted intervention. Signal Transduct. Target. Ther. 2021 6 1 263 10.1038/s41392‑021‑00658‑5 34248142
    [Google Scholar]
  27. Chen T. Ruan Y. Ji L. S100A6 drives lymphatic metastasis of liver cancer via activation of the RAGE/NF-kB/VEGF-D pathway. Cancer Lett. 2024 587 216709 10.1016/j.canlet.2024.216709 38350547
    [Google Scholar]
  28. Kiss E. Forika G. Dank M. Krenacs T. Nemeth Z. Methyl donors reduce cell proliferation by diminishing erk-signaling and nfkb levels, while increasing e-cadherin expression in panc-1 cell line. Int. J. Mol. Sci. 2022 23 5 2546 10.3390/ijms23052546 35269689
    [Google Scholar]
  29. Li Z. Feiyue Z. Gaofeng L. Traditional chinese medicine and lung cancer-from theory to practice. Biomed. Pharmacother. 2021 137 111381 10.1016/j.biopha.2021.111381 33601147
    [Google Scholar]
  30. Fu C. Zhang Y. Xi W. Dahuang Zhechong pill attenuates hepatic sinusoidal capillarization in liver cirrhosis and hepatocellular carcinoma rat model via the MK/integrin signaling pathway. J. Ethnopharmacol. 2023 308 116191 10.1016/j.jep.2023.116191 36731809
    [Google Scholar]
  31. Hu Q. Zhang W. Wu Z. Baicalin and the liver-gut system: Pharmacological bases explaining its therapeutic effects. Pharmacol. Res. 2021 165 105444 10.1016/j.phrs.2021.105444 33493657
    [Google Scholar]
/content/journals/pra/10.2174/0115748928379439250621171215
Loading
Dahuang Zhechong Pill Combined with TNS4 Silencing Inhibits the NF-Κb/VEGF Pathway To Slow Down The Progression Of Pancreatic Cancer
Bentham Science Publishers ; https://doi.org/10.2174/0115748928379439250621171215
/content/journals/pra/10.2174/0115748928379439250621171215
/content/journals/pra/10.2174/0115748928379439250621171215
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: inflammation ; Dahuang Zhechong Pill ; Traditional Chinese Medicine ; TNS4 ; NF-κB/VEGF pathway ; pancreatic cancer

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test